Myelodysplastic syndrome
ORPHA:52688Clinical groupAll ages
Ассоциированные гены1
Эпидемиология17
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 1.5 | Europe | Value and class |
| Lifetime Prevalence | 1-9 / 100 000 | 5.02 | Europe | Value and class |
| Annual incidence | 1-9 / 100 000 | 4.15 | Germany | Value and class |
| Point prevalence | 1-9 / 100 000 | 7 | Germany | Value and class |
| Annual incidence | 1-9 / 100 000 | 6.4 | France | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.35 | Japan | Value and class |
| Annual incidence | 1-9 / 100 000 | 3.35 | United States | Value and class |
| Annual incidence | 1-9 / 100 000 | 5.4 | Greece | Value and class |
| Annual incidence | 1-9 / 100 000 | 8.5 | United Kingdom | Value and class |
| Annual incidence | 1-9 / 100 000 | 3.5 | Sweden | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.5 | Romania | Value and class |
| Annual incidence | 1-9 / 100 000 | 8.1 | Spain | Value and class |
| Point prevalence | 1-5 / 10 000 | 15 | United States | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Europe | Class only |
| Annual incidence | 1-9 / 100 000 | 1.95 | Poland | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.2 | Poland | Value and class |
| Annual incidence | 1-9 / 100 000 | 3.8 | Switzerland | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)